Wed, February 8, 2012
[ Wed, Feb 08th 2012 ] - Market Wire
Tulks Hill Joint Venture Update
[ Wed, Feb 08th 2012 ] - Market Wire
News Release
Tue, February 7, 2012
Mon, February 6, 2012
Sun, February 5, 2012
Sat, February 4, 2012
Fri, February 3, 2012
Thu, February 2, 2012
Wed, February 1, 2012

Titan Pharmaceuticals to Present at 14th Annual BIO CEO &;; Investor Conference


//business-finance.news-articles.net/content/201 .. nnual-bio-ceo-amp-59-59-investor-conference.html
Published in Business and Finance on by Market Wire   Print publication without navigation


February 06, 2012 07:00 ET

Titan Pharmaceuticals to Present at 14th Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, CA--(Marketwire - Feb 6, 2012) - Titan Pharmaceuticals, Inc. (OTCBB: [ TTNP ]) today announced that company President Sunil Bhonsle will present during the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012 at 9 a.m. ET. The presentation will be webcast from the conference being held in New York City.

To access the presentation online, please visit [ www.titanpharm.com ] or [ http://www.veracast.com/webcasts/bio/ceoinvestor2012/51103193.cfm ]. A replay of the webcast will be made available through the link on the Titan website approximately 24 hours after the live presentation and the replay will be archived for 90 days.

About Titan Pharmaceuticals
For information concerning Titan Pharmaceuticals, Inc., please visit the company's website at [ www.titanpharm.com ].

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.



Publication Contributing Sources